Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Io Biotech Inc (IOBT)

Io Biotech Inc (IOBT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 50,127
  • Shares Outstanding, K 71,949
  • Annual Sales, $ 0 K
  • Annual Income, $ -95,490 K
  • EBIT $ -92 M
  • EBITDA $ -92 M
  • 60-Month Beta 0.47
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 28.06
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.50
  • Most Recent Earnings $-0.28 on 11/14/25
  • Next Earnings Date 11/18/25
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.16
  • Number of Estimates 3
  • High Estimate -0.09
  • Low Estimate -0.21
  • Prior Year -0.48
  • Growth Rate Est. (year over year) +66.67%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5880 +18.49%
on 12/02/25
0.9738 -28.46%
on 11/10/25
-0.1931 (-21.70%)
since 11/05/25
3-Month
0.3234 +115.43%
on 09/29/25
2.0800 -66.50%
on 09/12/25
-1.2533 (-64.27%)
since 09/05/25
52-Week
0.3234 +115.43%
on 09/29/25
2.7900 -75.03%
on 08/18/25
-0.1223 (-14.93%)
since 12/05/24

Most Recent Stories

More News
IO Biotech Announces Participation in Upcoming December Investor Conferences

NEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today...

IOBT : 0.6967 (+2.74%)
IO Biotech Reports Third Quarter 2025 Financial Results and Provides Business Highlights

Topline data from Phase 3 (IOB-013) clinical trial in advanced melanoma presented at ESMO; data highlights improvements in PFS achieved in overall population and across virtually all subgroups, although...

IOBT : 0.6967 (+2.74%)
IO Biotech Announces Participation in Upcoming Investor Conferences

NEW YORK, Nov. 12, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today...

IOBT : 0.6967 (+2.74%)
IO Biotech Presents Pre-Clinical Data Highlighting the Potential of Additional Therapeutic Cancer Vaccine Candidates at the 2025 Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Pre-clinical data for IO Biotech’s next T-win vaccine candidate, IO112 targeting arginase 1, demonstrates anti-tumor activity with dynamic changes in the tumor microenvironment (TME) driven by the vaccine-targeted...

IOBT : 0.6967 (+2.74%)
Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology

EQNX::TICKER_START (OTCQB:OTLC),(NASDAQ:IOBT),(NYSE:NVS),(NASDAQ:BCAX),(NYSE:PFE) EQNX::TICKER_END

BCAX : 18.20 (-2.99%)
OTLC : 0.0938 (+1.41%)
IOBT : 0.6967 (+2.74%)
NVS : 132.16 (-0.20%)
PFE : 26.03 (+1.28%)
IO Biotech Presents Phase 3 Results for Cylembio® plus KEYTRUDA® (pembrolizumab) in First-line Advanced Melanoma at ESMO 2025

Cylembio plus pembrolizumab achieved a clinically relevant 19.4 months median progression free survival (mPFS) compared to 11.0 months mPFS with pembrolizumab alone; study narrowly missed progression free...

IOBT : 0.6967 (+2.74%)
Precision Oncology Platforms Converge as FDA Accelerates Treatment Innovation

Issued on behalf of GT Biopharma, Inc. VANCOUVER – Baystreet.ca News Commentary – The convergence of advanced diagnostics and targeted therapeutics is reshaping cancer care, as September 2025...

LNTH : 63.30 (+2.31%)
GEHC : 85.46 (+3.56%)
SNDX : 20.32 (+2.94%)
IOBT : 0.6967 (+2.74%)
GTBP : 0.6094 (-3.24%)
Clinical Breakthroughs Converge as Immunotherapy Market Surges Past $136 Billion

EQNX::TICKER_START (NASDAQ:GTBP),(NASDAQ:LPTX),(NASDAQ:IOBT),(NASDAQ:CELC),(NYSE:MAIA) EQNX::TICKER_END

CELC : 105.63 (-0.23%)
GTBP : 0.6094 (-3.24%)
IOBT : 0.6967 (+2.74%)
LPTX : 2.0500 (+368.57%)
MAIA : 1.2000 (unch)
IO Biotech Provides Update Following Pre-BLA Meeting with FDA

FDA recommends that IO Biotech not submit a Biologics License Application (BLA) based on the data from the IOB-013 clinical trial Company plans to design new registrational study for Cylembio for the...

IOBT : 0.6967 (+2.74%)
IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

Oral presentation will highlight the results from the randomized Phase 3 trial (IOB-013/KN-D18) of IO102-IO103 cancer vaccine plus pembrolizumab for first-line (1L) advanced melanoma Poster presentation...

IOBT : 0.6967 (+2.74%)

Business Summary

IO Biotech Inc. is a clinical-stage biopharmaceutical company. It involved in developing novel, immune-modulating cancer therapies based on its T-win(R) technology platform. IO Biotech Inc. is based in WILMINGTON, Del.

See More

Key Turning Points

3rd Resistance Point 0.8220
2nd Resistance Point 0.7910
1st Resistance Point 0.7438
Last Price 0.6967
1st Support Level 0.6656
2nd Support Level 0.6346
3rd Support Level 0.5874

See More

52-Week High 2.7900
Fibonacci 61.8% 1.8478
Fibonacci 50% 1.5567
Fibonacci 38.2% 1.2656
Last Price 0.6967
52-Week Low 0.3234

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar